Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Head and neck

1851 - Comparing Survival outcomes in operable treatment naïve T4b and T4a oral cavity cancers (341O)

Date

18 Nov 2017

Session

Head and neck

Presenters

Manish Mair

Citation

Annals of Oncology (2017) 28 (suppl_10): x100-x110. 10.1093/annonc/mdx665

Authors

M.D. Mair, S. Nair, P. Chaturvedi

Author affiliations

  • Head And Neck, TATA MEMEORIAL HOSPITAL, 400092 - mumbai/IN
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1851

Background

T4 disease is divided as T4a (moderately advanced) and T4b (very advanced) for oral cavity cancers as per American Joint Committee on cancer (AJCC) 7th edition. Liao et al showed no statistical difference in the 5-year survival rates between the T4a and T4b groups. But it was a retrospective study with a small sample size. Thus, there was a need of a prospective study comparing the survival outcomes between T4a and T4b lesions.

Methods

This is a prospective study of 210 treatment naïve biopsy proven T4 buccal mucosa cancer patients operated between January 2010 to December 2013.Surgery was the primary modality of treatment followed by adjuvant therapy. Patients with Extracapsular spread(ECS) and margin positivity received chemoradiation and remaining patients received radiation alone. Follow up was done every 3 months. In the case of clinical suspicion of recurrence, confirmation was done using biopsy and or imaging.

Results

The mean age was 49 years (26-73 years) with a male to female ratio of 4.6:1. T4a disease was seen in 135(64.3%) patients and T4b in 75(35.7%) patients. The mean disease-free survival(DFS) in T4a and T4b group was 41 months and 30 months respectively(p-0.001).The mean overall survival was 46 months for T4a lesion and 30 months for T4b lesion(p-0.0012). Differences in the DFS of the patients who received chemoradiation and those who received only radiation is given in the Table below. As expected, it is seen that patients with Extracapsular spread(ECS) and margin positivity have poor survival. But it is difficult to explain why patients with T4b disease without ECS or positive margins also have poor survival. Intensification of treatment in these select group of patients is important which might improve outcomes. Also, the rate of distant metastasis in patients with T4b disease was 19% and among those with T4a disease was 11%.Table: 341O

3 –year DFST4aT4b
Chemo-radiation(with ECS & margin positivity)41.6%33.6%
Radiation alone72.2%42.1%
p-value0.0000.074

Conclusions

T4b is more aggressive disease than T4a.Treatment intensification with the addition of chemotherapy to radiation may benefit select patients with T4b buccal mucosa cancers and might help in reducing the rate of distant metastasis.

Clinical trial identification

Legal entity responsible for the study

Manish Mair

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.